GET DAILY SIGNALSWhy Is SANUWAVE Health (SNWV) Stock Down -58.12% Today?
Key Takeaways
- SNWV shares plunged roughly 58% on November 5, 2026, after CMS finalized a 21% cut to Medicare reimbursement for the company's core UltraMIST therapy.
- The primary catalyst was the Calendar Year 2027 Medicare Physician Fee Schedule final rule, released after the prior session's close.
- Secondary pressure came from the prospect of a further reimbursement reduction in 2028 and an outstanding Nasdaq delisting notice.
- The hospital outpatient rate for the same CPT code rose 15%, partially offsetting the office-setting cut but not enough to reassure investors.
- Traders are watching the company's upcoming earnings call and any response or lobbying effort aimed at the final rule.
- For more detail on valuation and projections, explore Price Targets, Earnings, and Forecast data for SNWV.
- To see which strategies are performing best right now, explore Trending AI Robots.
Opening Summary
SANUWAVE Health, Inc. (SNWV), a Minnesota-based medical device company that develops FDA-cleared directed-energy wound-care systems led by its UltraMIST ultrasound therapy, saw its stock collapse on Thursday. Shares tumbled roughly 58% to about $2.40, down from the previous session's close of $5.73, after a Medicare reimbursement ruling struck at the heart of the company's core product economics. The move marks one of the steepest single-day declines for the micro-cap name and reflects a sharp repricing of its revenue outlook.
Catalyst Breakdown: CMS Reimbursement Cut
The dominant driver was the Centers for Medicare & Medicaid Services (CMS) Calendar Year 2027 Physician Fee Schedule final rule, released after the market closed on November 4, 2026. Under the rule, the national Medicare payment for CPT code 97610 — the code under which UltraMIST ultrasound therapy is billed in physician offices and mobile clinics — falls to $314.54 per treatment in 2027, down roughly 21% from $397.81 in 2026.
Because a meaningful share of SNWV's installed base operates in physician-office settings, investors interpreted the cut as a direct hit to the economics of the company's flagship therapy. The company noted that the first-year reduction was capped at 19% of total relative value units (RVUs), with the remainder phased in during 2028 — meaning an even deeper cut is likely next year absent further rulemaking.
Secondary Drivers: 2028 Risk and Delisting Overhang
Compounding the immediate reimbursement shock, CMS final rule filings indicate the non-facility practice expense RVU for code 97610 will decline further at full phase-in in 2028. Management said it "expects a significant further reduction" in the 2028 rate, extending the revenue uncertainty well beyond a single year.
The sell-off also played out against a pre-existing overhang: the company received a Nasdaq delisting notice in late September 2026, raising liquidity and listing-compliance concerns for a stock already trading thinly. The reimbursement ruling amplified those concerns, prompting investors to reassess the risk profile of a company whose guidance had already been withdrawn amid regulatory uncertainty.
Market Context and Trading Activity
The decline was decisive rather than gradual, with the stock gapping down and remaining under heavy pressure through the session. Trading activity was elevated relative to SNWV's typically thin daily volume, consistent with a broad repricing event in a low-float, micro-cap name. The stock sliced through its recent trading range and its 50-day moving average, leaving it trading well below levels seen just days earlier.
The move was company-specific rather than a reflection of broader market weakness; healthcare and broader indices did not experience a comparable drawdown. Notably, the hospital outpatient prospective payment rule simultaneously raised the 97610 rate by 15% to $235.04, a partial offset that failed to calm investors focused on the larger physician-office cut.
What Comes Next for SNWV
Attention now turns to SNWV's upcoming earnings call, where management is expected to address the financial impact of the final rule and outline its response strategy. The company has said it disputes CMS's cost assumptions and "plans to continue to engage" with the agency, arguing the rule undervalues UltraMIST treatment and underestimates provider costs.
Key uncertainties include whether the company can shift utilization toward the higher-paying hospital outpatient setting, how quickly it can diversify revenue, and whether its ongoing compliance efforts resolve the Nasdaq listing warning. Until clarity emerges on the 2028 rate and any potential regulatory reconsideration, the stock is likely to remain volatile.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are currently among the strongest performers across the market. Tickeron offers hundreds of bots covering thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and traded symbols. Explore the page to see which automated strategies are thriving under today's conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for SNWV shows an upward move is likely
SNWV's Aroon Indicator triggered a bullish signal on October 21, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 83 similar instances where the Aroon Indicator showed a similar pattern. In 75 of the 83 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on SNWV as a result. In 113 of 128 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for SNWV just turned positive on November 02, 2026. Looking at past instances where SNWV's MACD turned positive, the stock continued to rise in 60 of 67 cases over the following month. The odds of a continued upward trend are 90%.
SNWV moved above its 50-day moving average on October 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SNWV crossed bullishly above the 50-day moving average on October 08, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Following a +15.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNWV advanced for three days, in 160 of 195 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for SNWV moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 13 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNWV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
SNWV broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.686) is normal, around the industry mean (4.338). P/E Ratio (3.219) is within average values for comparable stocks, (1.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.873) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. SNWV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNWV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement